Adx-097
Iga Nephropathy, Lupus Nephritis (Ln), C3 (Complement Component 3) Glomerulopathy
Phase II
Withdrawn
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
May 08, 2024
―
Adx-914
Atopic Dermatitis
Phase II
Active Not Recruiting
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
Aug 12, 2022
―
Adx-914
Safety Issues
Phase I
Completed
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
Jul 21, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Q32 Bio (DB0) have in its pipeline
DB0 is currently developing the following drugs: Adx-097, Bempikibart (Adx-914), Adx-914. These drug candidates are in various stages of clinical development as the company works toward FDA approval.